Kornitzer Capital Management Inc. KS Sells 15,696 Shares of IQVIA Holdings Inc. $IQV

Key Points

• Kornitzer Capital Management cut its stake in IQVIA by 59.7% in Q4, selling 15,696 shares and ending the period with 10,600 shares valued at $2.389 million.
• IQVIA beat quarterly estimates with $3.42 EPS (vs. $3.40) and $4.36B revenue (up 10.3% YoY), and set FY2026 EPS guidance of 12.550–12.850.
• Analysts are broadly positive (average rating "Buy") with an average price target of $226.63; the stock recently traded around $157.73 with a 1‑year range of $134.65–$247.04 and a market cap of about $26.8B.

Kornitzer Capital Management Inc. KS lowered its stake in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 59.7% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 10,600 shares of the medical research company's stock after selling 15,696 shares during the period. Kornitzer Capital Management Inc. KS's holdings in IQVIA were worth $2,389,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Ameliora Wealth Management Ltd. bought a new stake in IQVIA in the fourth quarter valued at $25,000. Physician Wealth Advisors Inc. boosted its holdings in IQVIA by 1,340.0% in the third quarter. Physician Wealth Advisors Inc. now owns 144 shares of the medical research company's stock valued at $27,000 after acquiring an additional 134 shares in the last quarter. Westside Investment Management Inc. boosted its holdings in IQVIA by 219.6% in the third quarter. Westside Investment Management Inc. now owns 147 shares of the medical research company's stock valued at $30,000 after acquiring an additional 101 shares in the last quarter. Measured Wealth Private Client Group LLC bought a new stake in shares of IQVIA during the 3rd quarter valued at $30,000. Finally, Activest Wealth Management boosted its holdings in shares of IQVIA by 590.0% during the 4th quarter. Activest Wealth Management now owns 138 shares of the medical research company's stock valued at $31,000 after buying an additional 118 shares in the last quarter. Institutional investors own 89.62% of the company's stock.

IQVIA Price Performance

IQV opened at $157.73 on Friday. The stock has a 50-day moving average price of $169.36 and a 200-day moving average price of $201.55. The company has a debt-to-equity ratio of 2.09, a current ratio of 0.75 and a quick ratio of 0.75. The firm has a market cap of $26.77 billion, a PE ratio of 20.07, a P/E/G ratio of 1.57 and a beta of 1.18. IQVIA Holdings Inc. has a 1 year low of $134.65 and a 1 year high of $247.04.

IQVIA (NYSE:IQV - Get Free Report) last posted its quarterly earnings results on Thursday, February 5th. The medical research company reported $3.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.40 by $0.02. The firm had revenue of $4.36 billion during the quarter, compared to analyst estimates of $4.24 billion. IQVIA had a return on equity of 30.50% and a net margin of 8.34%.IQVIA's quarterly revenue was up 10.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $3.12 EPS. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. Sell-side analysts predict that IQVIA Holdings Inc. will post 11.5 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have recently commented on the stock. Mizuho set a $215.00 target price on shares of IQVIA in a report on Monday, February 23rd. Barclays upgraded shares of IQVIA from an "equal weight" rating to an "overweight" rating and set a $210.00 target price on the stock in a report on Friday, March 6th. Citigroup dropped their target price on shares of IQVIA from $230.00 to $200.00 and set a "neutral" rating on the stock in a report on Friday, February 6th. Jefferies Financial Group dropped their target price on shares of IQVIA from $270.00 to $255.00 and set a "buy" rating on the stock in a report on Friday, February 6th. Finally, TD Cowen upgraded shares of IQVIA from a "hold" rating to a "buy" rating and boosted their target price for the company from $174.00 to $213.00 in a report on Monday, March 9th. Two analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat.com, the company has an average rating of "Buy" and an average price target of $226.63.

IQVIA Profile

IQVIA NYSE: IQV is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA's principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.